Alfred Clinical Trials

Alfred Health has more than 700 open trials across 20 clinical disciplines, our clinical trial portfolio is one of the largest in the country.

Clear filter
604 clinical trials found
Clinical trials

ENHANCE 2

A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician’s Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia (NCT04778397)

Recently completed/closed

RELATIVITY-127

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma (NCT05625399)

Currently recruiting

M23-698

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (NCT05889182)

Currently recruiting

CA0711000

A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor [ARPI], in Participants with Metastatic Castration-resistant Prostate Cancer [mCRPC] - rechARge (NCT06764485)

Currently recruiting

CA057-001

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (NCT05519085)

Currently recruiting

ExcaliBER

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Iberdomide, Daratumumab and Dexametasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (NCT04975997)

Currently recruiting

ENVISION

A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease (NCT05310071)

No longer recruiting

CS2009

A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a tri-specific antibody targeting PD-1/VEGFA/CTLA-4, in Participants with Advanced Solid Tumors (NCT06741644)

Currently recruiting

BP44474

A PHASE I, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF RO7589831 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MICROSATELLITE INSTABILITY [MSI] AND/OR DEFICIENT MISMATCH REPAIR [DMMR] (NCT06004245)

Currently recruiting

GO41751

A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BLYG8824A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER (NCT04468607)

Currently recruiting

ERASER

A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy with Nivolumab in Patients with Advanced Solid Tumors and Hematological Malignancies (NCT04305249)

No longer recruiting

ATRIUM

A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid Tumors and Hematological Malignancies (NCT05338346)

No longer recruiting

BelaCarD

A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma. (ACTRN12620000490976)

Currently recruiting

LM108-01-101

A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as a Single Agent or in Combination with Anti-PD-1 Antibody in Subjects with Advanced Solid Tumours (NCT05199753)

Currently recruiting

GB261-001

A Phase I/II, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GB261 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (GB261-001) (NCT04923048)

Currently recruiting

AZD0305

A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of AZD0305 in Patients with Relapsed or Refractory Multiple Myeloma (NCT06106945)

Currently recruiting

LM302

A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM302 in Combination with Toripalimab in Patients with Advanced Solid Tumors (NCT05188664)

No longer recruiting

SUPERNOVA [Phase 3]

A Phase I/III Randomized, Double-blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment (NCT05648110)

Currently recruiting

GO42144

A PHASE Ia/Ib DOSE-ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION (NCT04449874)

Currently recruiting

BO45287

A phase Ib open-label, multicenter study evaluating the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

Coming soon
10 11 12 13 14